CODEXIS Earnings Results: $CDXS Reports Quarterly Earnings
Earnings Report: CODEXIS reported quarterly earnings of -$0.25 per share, missing estimates, and revenue of $7,540,000, which also fell short of expectations by over $2 million.
Insider Trading Activity: In the past six months, CODEXIS insiders have made 22 stock purchases with no sales, while institutional investors have shown mixed activity, with 74 adding shares and 56 reducing their positions.
Trade with 70% Backtested Accuracy
Analyst Views on CDXS
No data
About CDXS
About the author
Codexis Partners with Axolabs to Evaluate RNA Manufacturing Platform
- Partnership Agreement: Codexis and Axolabs have signed an agreement for Axolabs to evaluate Codexis' ECO Synthesis Manufacturing Platform, aimed at enhancing the efficient manufacturing of RNA therapeutics, which is expected to significantly improve market access capabilities.
- Technological Innovation: The platform utilizes enzymatic synthesis technology, enabling more sustainable and cost-effective production to meet large-scale manufacturing demands, thereby enhancing both companies' competitiveness in the nucleic acid therapeutics sector.
- Market Potential: Codexis CEO Alison Moore stated that this collaboration will expand the reach of the ECO Synthesis Manufacturing Platform, helping to meet the rapidly growing demand for nucleic acid drugs and potentially paving the way for future licensing discussions.
- Industry Leadership: The combination of Axolabs' technological leadership and Codexis' innovative capabilities reinforces both companies' commitment to providing high-quality oligonucleotide medicines globally, driving the industry towards more efficient manufacturing models.
Codexis Partners with Axolabs to Enhance RNA Manufacturing with ECO Synthesis Platform
- Partnership Agreement: Codexis and Axolabs have entered into an agreement for Axolabs to evaluate Codexis' ECO Synthesis Manufacturing Platform, marking a strategic collaboration in efficient RNA manufacturing that is expected to pave the way for future licensing discussions and broader platform adoption.
- Innovation Potential: Axolabs' Senior Director of Operations noted that this technology could be pivotal for large-scale manufacturing of therapeutic oligonucleotides, enabling more sustainable and cost-effective production, which aligns with market demands for high-quality drugs.
- Market Expansion Strategy: Codexis CEO Alison Moore emphasized the mission to expand the reach of the ECO Synthesis Manufacturing Platform through collaborations with leading CDMOs, thereby enhancing the company's competitive position in the rapidly growing RNA therapeutics market.
- Global Drug Accessibility: This collaboration not only reinforces the commitment of both Codexis and Axolabs to excellence but also aims to enhance global access to high-quality oligonucleotide-based medicines, addressing the increasing market demand.
Tarsus Pharmaceuticals, Inc. (TARS) Posts Q3 Loss but Exceeds Revenue Projections
Quarterly Performance: Tarsus Pharmaceuticals reported a quarterly loss of $0.30 per share, better than the expected loss of $0.35, and significantly improved from a loss of $0.61 per share a year ago, marking a 14.29% earnings surprise.
Revenue Growth: The company achieved revenues of $118.7 million for the quarter, exceeding the Zacks Consensus Estimate by 2.80% and showing substantial growth from $48.12 million in the same quarter last year.
Stock Outlook: Tarsus Pharmaceuticals has seen a 26% increase in its stock price since the beginning of the year, outperforming the S&P 500, but the future performance will depend on management's commentary and earnings estimate revisions.
Industry Context: The Medical - Biomedical and Genetics industry, where Tarsus operates, ranks in the top 39% of Zacks industries, indicating a favorable outlook, while Codexis, another company in the same sector, is set to report its quarterly results soon.
Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing
Collaboration Announcement: Codexis, Inc. and Nitto Denko Avecia, Inc. have entered into an evaluation agreement to assess Codexis' ECO Synthesis® Manufacturing Platform for oligonucleotide therapeutics.
Innovative Manufacturing Approach: The ECO Synthesis platform aims to replace traditional solid-phase oligonucleotide synthesis with a more flexible, enzyme-catalyzed method designed for scalability and sustainability in therapeutic development.
Leadership Statements: Both companies' executives expressed enthusiasm for the partnership, highlighting its potential to advance the manufacturing of high-quality therapeutics and redefine industry standards.
Company Backgrounds: Codexis is known for its enzymatic solutions in therapeutic manufacturing, while Nitto Denko Avecia specializes in oligonucleotide therapeutics, boasting extensive experience and a comprehensive service portfolio.
Codexis Scheduled to Release Q3 2025 Financial Results on November 6
Financial Results Announcement: Codexis, Inc. will report its third-quarter financial results on November 6, 2025, after market close, followed by a conference call at 4:30 pm ET for discussion and updates.
Accessing the Call: Participants can join the live webcast on the Codexis Investor Relations website, with a replay available for 48 hours via specific phone numbers.
Company Overview: Codexis specializes in enzymatic solutions for manufacturing complex therapeutics, utilizing its CodeEvolver® technology to enhance enzyme performance and efficiency.
Innovative Manufacturing Platform: The company is developing the ECO Synthesis™ platform to facilitate the scalable production of RNAi therapeutics through enzymatic methods, aiming for higher yields and reduced environmental impact.
Codexis Revenue Jumps 91 Percent in Q2
Financial Performance: Codexis reported a 91.3% year-over-year revenue increase to $15.3 million in Q2 2025, surpassing estimates, while net loss per share improved to ($0.16) from ($0.32) in the previous year, indicating progress despite ongoing operational costs.
Strategic Developments: The company is focusing on expanding its ECO Synthesis platform for RNA therapeutics, achieving significant milestones with contract manufacturing partners, and aims for cash flow positivity by the end of 2026 through new business contracts and partnerships.
Codexis Partners with Axolabs to Evaluate RNA Manufacturing Platform
- Partnership Agreement: Codexis and Axolabs have signed an agreement for Axolabs to evaluate Codexis' ECO Synthesis Manufacturing Platform, aimed at enhancing the efficient manufacturing of RNA therapeutics, which is expected to significantly improve market access capabilities.
- Technological Innovation: The platform utilizes enzymatic synthesis technology, enabling more sustainable and cost-effective production to meet large-scale manufacturing demands, thereby enhancing both companies' competitiveness in the nucleic acid therapeutics sector.
- Market Potential: Codexis CEO Alison Moore stated that this collaboration will expand the reach of the ECO Synthesis Manufacturing Platform, helping to meet the rapidly growing demand for nucleic acid drugs and potentially paving the way for future licensing discussions.
- Industry Leadership: The combination of Axolabs' technological leadership and Codexis' innovative capabilities reinforces both companies' commitment to providing high-quality oligonucleotide medicines globally, driving the industry towards more efficient manufacturing models.
Codexis Partners with Axolabs to Enhance RNA Manufacturing with ECO Synthesis Platform
- Partnership Agreement: Codexis and Axolabs have entered into an agreement for Axolabs to evaluate Codexis' ECO Synthesis Manufacturing Platform, marking a strategic collaboration in efficient RNA manufacturing that is expected to pave the way for future licensing discussions and broader platform adoption.
- Innovation Potential: Axolabs' Senior Director of Operations noted that this technology could be pivotal for large-scale manufacturing of therapeutic oligonucleotides, enabling more sustainable and cost-effective production, which aligns with market demands for high-quality drugs.
- Market Expansion Strategy: Codexis CEO Alison Moore emphasized the mission to expand the reach of the ECO Synthesis Manufacturing Platform through collaborations with leading CDMOs, thereby enhancing the company's competitive position in the rapidly growing RNA therapeutics market.
- Global Drug Accessibility: This collaboration not only reinforces the commitment of both Codexis and Axolabs to excellence but also aims to enhance global access to high-quality oligonucleotide-based medicines, addressing the increasing market demand.
Tarsus Pharmaceuticals, Inc. (TARS) Posts Q3 Loss but Exceeds Revenue Projections
Quarterly Performance: Tarsus Pharmaceuticals reported a quarterly loss of $0.30 per share, better than the expected loss of $0.35, and significantly improved from a loss of $0.61 per share a year ago, marking a 14.29% earnings surprise.
Revenue Growth: The company achieved revenues of $118.7 million for the quarter, exceeding the Zacks Consensus Estimate by 2.80% and showing substantial growth from $48.12 million in the same quarter last year.
Stock Outlook: Tarsus Pharmaceuticals has seen a 26% increase in its stock price since the beginning of the year, outperforming the S&P 500, but the future performance will depend on management's commentary and earnings estimate revisions.
Industry Context: The Medical - Biomedical and Genetics industry, where Tarsus operates, ranks in the top 39% of Zacks industries, indicating a favorable outlook, while Codexis, another company in the same sector, is set to report its quarterly results soon.
Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing
Collaboration Announcement: Codexis, Inc. and Nitto Denko Avecia, Inc. have entered into an evaluation agreement to assess Codexis' ECO Synthesis® Manufacturing Platform for oligonucleotide therapeutics.
Innovative Manufacturing Approach: The ECO Synthesis platform aims to replace traditional solid-phase oligonucleotide synthesis with a more flexible, enzyme-catalyzed method designed for scalability and sustainability in therapeutic development.
Leadership Statements: Both companies' executives expressed enthusiasm for the partnership, highlighting its potential to advance the manufacturing of high-quality therapeutics and redefine industry standards.
Company Backgrounds: Codexis is known for its enzymatic solutions in therapeutic manufacturing, while Nitto Denko Avecia specializes in oligonucleotide therapeutics, boasting extensive experience and a comprehensive service portfolio.
Codexis Scheduled to Release Q3 2025 Financial Results on November 6
Financial Results Announcement: Codexis, Inc. will report its third-quarter financial results on November 6, 2025, after market close, followed by a conference call at 4:30 pm ET for discussion and updates.
Accessing the Call: Participants can join the live webcast on the Codexis Investor Relations website, with a replay available for 48 hours via specific phone numbers.
Company Overview: Codexis specializes in enzymatic solutions for manufacturing complex therapeutics, utilizing its CodeEvolver® technology to enhance enzyme performance and efficiency.
Innovative Manufacturing Platform: The company is developing the ECO Synthesis™ platform to facilitate the scalable production of RNAi therapeutics through enzymatic methods, aiming for higher yields and reduced environmental impact.
Codexis Revenue Jumps 91 Percent in Q2
Financial Performance: Codexis reported a 91.3% year-over-year revenue increase to $15.3 million in Q2 2025, surpassing estimates, while net loss per share improved to ($0.16) from ($0.32) in the previous year, indicating progress despite ongoing operational costs.
Strategic Developments: The company is focusing on expanding its ECO Synthesis platform for RNA therapeutics, achieving significant milestones with contract manufacturing partners, and aims for cash flow positivity by the end of 2026 through new business contracts and partnerships.
